ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar 2tal (< 20) Submitted: 4/10/2007 1:50:12 PM : Outperform Start Price: $8.40 ARQL Score: -26.64

A biotech that is starting to hit its stride. The stock is starting to move regularly and in the right direction.

Featured Broker Partners


Advertisement